🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

NEW-Tranexamic acid did not prevent bleeding in patients with haematological malignancies and severe thrombocytopenia compared to placebo: results from the randomised, double-blind, parallel, phase 3, TREATT trial thelancet.com/journals/lanha…

Only 10 days left before the draw!! Buy a ticket today and support Thrombosis Ireland this Christmas! Great prizes to be won. Click to purchase 👇 idonate.ie/raffle/Christm… World Thrombosis Day ISTH Fiona M Hanrahan NVTEP @NationalQPS Niamh O'Hanlon Barry Kevane K Ewins Sarah Garvey

Oral HRT increases venous thrombotic risk (VTE). Tibolone increases arterial but not VTE risk. Topical HRT showed no increase in either. Huge prospective Swedish study: 919,614 women of whom 77,512 started HRT. tinyurl.com/85jxatux #HRT

🧠💉 Pediatric CSVT most often affects neonates & young kids, often linked to head/neck infections. 🩸 Data from the Kids-DOTT trial suggest 6 weeks of anticoagulation is safe & effective, with no recurrent VTE or significant bleeding rpthjournal.org/article/S2475-…

ASH Late Breaking Abstract: Should patients receive extended duration anticoagulation with reduced or full dose DOAC for the secondary prevention of recurrent VTE - The RENOVE RCT presented by Francis Couturaud Reduced dose DOAC was not non inferior to full dose ((5-year

🩸 How to manage severe #bleeding in patients on oral anticoagulant? ⤵️ 📖 Siraj Mithoowani and colleagues provide multidisciplinary expert guidance for managing bleeding during #OAC 🆓 on TH 👉 thieme-connect.de/products/ejour… #Anticoagulant #Thrombosis #Bleeding SETH Trombosis y Hemostasia

Pleased to share this perspective on andexanet alfa, now published in RPTH #openaccess🔓 rpthjournal.org/article/S2475-… I cover blinding, surrogate endpoints, clinical outcomes and thrombosis. A brief 🧵

Prof. Mahé Isabelle presents API-CAT at #ACC2025, published in NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…

Practice-changing paper in @nejm by Mahé Isabelle Marc Carrier API-CAT team proves that apixaban dose can be reduced after 6mo of anticoag rx with no loss of efficacy and less bleeding. Congrats to the team! nejm.org/doi/full/10.10…

Don't be fooled by Antiphospholipid Syndrome (APS)! Check out this Forum from Deepa Arachchillage and Mike Laffan about managing APS rpthjournal.org/article/S2475-…

Patients looking for answers to thrombosis-related questions will find our library of information sheets (27 in total), on topics ranging from understanding their diagnosis to managing their treatment, a valuable place to go. Check out our latest publication on CTEPH (Chronic

🔴Updated Definition & Scoring of Disseminated Intravascular Coagulation in 2025:⤵️ 🔹jthjournal.org/article/S1538-… #DIC #ISTH2025 #PBM #BMT #SIC #TIC #Sepsis #Hematology #CriticalCare #SOHO24 #HemePearls #Coagulopathy #Cardiology #FOAMed #MedEd

#DDAVP response and its determinants in #bleeding disorders: a systematic review and meta-analysis ashpublications.org/blood/article/…

Treatment of VTE does NOT end at discharge! 💡We need a clinical framework in place to follow pts and allow for early detection of post VTE symptoms and patient reported concerns that impact Quality of Life #ISTH2025 #VTE #AnticoagStewrship

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

Cobra Trial: #apixaban safer than #rivaroxaban for venous #thrombosis treatment #ISTH2025 ⁦Anticoagulation Forum⁩ ⁦Vasculearn Network⁩ ⁦The PERT Consortium®⁩ ⁦World Thrombosis Day⁩ ⁦Thrombosis Canada⁩ ⁦CanVECTOR Network⁩ ⁦European Thrombosis & Haemostasis Alliance (ETHA)⁩ ⁦C. Michael Gibson MD⁩ ⁦

🩸 Meta-analysis presented at #ISTH2025 and simultaneously published in EHJ Editor-in-Chief found that several risk factors (e.g., previous history of VTE or bleeding, advanced cancer, and specific cancer sites) are associated with recurrent VTE and bleeding in patients with CAT.

"Time is tissue" applies beyond MI and stroke. Dr. Bria et al. show ~2.7× higher odds of PE-related death in intermediate-risk PE when anticoagulation is delayed. It's time we emphasize Door-to-Anticoagulant in PE care. #ISTH2025 #ClassicalHem #MedTwitter

Do you dose reduce DOAC for extended prevention of VTE? 💙 Post hoc analysis of RENOVE trial of secondary prevention of VTE. ♥️ suggests low dose DOAC may be inferior to full dose among people with BMI >30. 💙 more data is needed #ISTH2025

🩸 New insights from the RENOVE trial (extended duration anticoagulation) at #ISTH2025: 📉 Reduced-dose DOAC is non-inferior in patients with BMI <30, with less bleeding risk. ⚠️ But in patients with BMI ≥30, reduced-dose may be inferior for bleeding and recurrent VTE. ➡️